Metformin, the first-line orally administered therapeutic for T2D, primarily functions by inhibiting gluconeogenesis in the liver2 but does not specifically target thermogenic adipocytes, insulin secretion or carbohydrate absorption. Here, INS is linked to type 2 diabetes mellitus.